Opthea Limited (NASDAQ:OPT – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $5.49, but opened at $5.68. Opthea shares last traded at $5.65, with a volume of 6,031 shares traded.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on OPT shares. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Opthea in a research report on Wednesday. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a research report on Tuesday, December 17th.
Get Our Latest Stock Report on Opthea
Opthea Stock Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. ABC Arbitrage SA purchased a new position in shares of Opthea in the 4th quarter valued at approximately $40,000. Twin Lakes Capital Management LLC purchased a new position in shares of Opthea in the 3rd quarter valued at approximately $81,000. Finally, Jane Street Group LLC purchased a new stake in shares of Opthea in the third quarter valued at approximately $114,000. 55.95% of the stock is currently owned by hedge funds and other institutional investors.
About Opthea
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Further Reading
- Five stocks we like better than Opthea
- 5 discounted opportunities for dividend growth investors
- The Best Way to Invest in Gold Is…
- Most Volatile Stocks, What Investors Need to Know
- Why Nike Stock Could Be 2025’s Top Comeback Play
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Uber Stock Gaining Speed: Analysts See 30% Upside
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.